These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31522184)

  • 1. Tacrolimus: Influence of the Posttransplant Concentration/Dose Ratio on Kidney Graft Function in a Two-Year Follow-Up.
    Nowicka M; Górska M; Nowicka Z; Edyko K; Edyko P; Wiślicki S; Zawiasa-Bryszewska A; Strzelczyk J; Matych J; Kurnatowska I
    Kidney Blood Press Res; 2019; 44(5):1075-1088. PubMed ID: 31522184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased renal function decline in fast metabolizers using extended-release tacrolimus after kidney transplantation.
    Thölking G; Filensky B; Jehn U; Schütte-Nütgen K; Koch R; Kurschat C; Pavenstädt H; Suwelack B; Reuter S; Kuypers D
    Sci Rep; 2021 Aug; 11(1):15606. PubMed ID: 34341448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation.
    Thölking G; Siats L; Fortmann C; Koch R; Hüsing A; Cicinnati VR; Gerth HU; Wolters HH; Anthoni C; Pavenstädt H; Suwelack B; Schmidt HH; Kabar I
    Ann Transplant; 2016 Mar; 21():167-79. PubMed ID: 27003330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trough Level and Tacrolimus Variability of Early Converted Once-Daily Tacrolimus: 1-Year Follow-up Study.
    Sukkha S; Suansanae T; Iamrahong P; Wiwattanathum P
    Transplant Proc; 2020 Apr; 52(3):775-779. PubMed ID: 32143870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of immunosuppressive treatment on homocystein levels in patients after kidney transplantation during a 2 year observation period].
    Aksamit D; Janda K; Kuźniewski M; Krzanowski M; Ignacak E; Betkowska-Prokop A; Chowaniec E; Sułowicz W
    Przegl Lek; 2012; 69(11):1175-9. PubMed ID: 23646442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tacrolimus metabolism rate influences renal function after kidney transplantation.
    Thölking G; Fortmann C; Koch R; Gerth HU; Pabst D; Pavenstädt H; Kabar I; Hüsing A; Wolters H; Reuter S; Suwelack B
    PLoS One; 2014; 9(10):e111128. PubMed ID: 25340655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fast Tac Metabolizers at Risk ⁻ It is Time for a C/D Ratio Calculation.
    Schütte-Nütgen K; Thölking G; Steinke J; Pavenstädt H; Schmidt R; Suwelack B; Reuter S
    J Clin Med; 2019 Apr; 8(5):. PubMed ID: 31035422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration.
    Andrés A; Budde K; Clavien PA; Becker T; Kessler M; Pisarski P; Fornara P; Burmeister D; Hené RJ; Cassuto-Viguier E;
    Transplantation; 2009 Nov; 88(9):1101-8. PubMed ID: 19898206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.
    Gralla J; Wiseman AC
    Transplantation; 2009 Jun; 87(11):1712-9. PubMed ID: 19502965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation.
    Kolonko A; Chudek J; Wiecek A
    Transplant Proc; 2011 Oct; 43(8):2950-3. PubMed ID: 21996198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
    Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
    Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to Everolimus was Beneficial and Safe for Fast and Slow Tacrolimus Metabolizers After Renal Transplantation.
    Thölking G; Gillhaus NH; Schütte-Nütgen K; Pavenstädt H; Koch R; Suwelack B; Reuter S
    J Clin Med; 2020 Jan; 9(2):. PubMed ID: 31979381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion from Prograf to Advagraf in stable kidney transplant recipients: better renal function after 3-year follow-up.
    Spagnoletti G; Gargiulo A; Salerno MP; Favi E; Pedroso JA; Calia R; Romagnoli J; Citterio F
    Transplant Proc; 2014 Sep; 46(7):2224-7. PubMed ID: 25242756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of a low-dose tacrolimus protocol on the appearance of de novo donor-specific antibodies during 7 years of follow-up after renal transplantation.
    Unagami K; Ishida H; Furusawa M; Kitajima K; Hirai T; Kakuta Y; Toki D; Shimizu T; Omoto K; Okumi M; Nitta K; Tanabe K
    Nephrol Dial Transplant; 2021 May; 36(6):1120-1129. PubMed ID: 33280052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colchicine levels in chronic kidney diseases and kidney transplant recipients using tacrolimus.
    Amanova A; Kendi Celebi Z; Bakar F; Caglayan MG; Keven K
    Clin Transplant; 2014 Oct; 28(10):1177-83. PubMed ID: 25125128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
    Chamienia A; Dębska-Ślizień A; Król E; Biedunkiewicz B; Rutkowski B
    Transplant Proc; 2014 Oct; 46(8):2714-8. PubMed ID: 25380901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody.
    Gonwa TA; Mai ML; Smith LB; Levy MF; Goldstein RM; Klintmalm GB
    Clin Transplant; 2002 Apr; 16(2):144-9. PubMed ID: 11966785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
    Morales JM; Andrés A; Dominguez-Gil B; Arriola M; Gutiérrez MJ; Hernández E; Ortuño T; Praga M
    Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study.
    Pankewycz O; Leca N; Kohli R; Weber-Shrikant E; Said M; Alnimri M; Feng L; Patel S; Laftavi MR
    Transplant Proc; 2011 Mar; 43(2):519-23. PubMed ID: 21440749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.